Communications
c) A. Fürstner, C. Nevado, M. Waser, M. Tremblay, C. Chevrier,
F. Teply, C. Aissa, E. Moulin, O. Müller, J.Am.Chem.Soc. 2007,
129, 9150 – 9161, and references therein.
The top scoring docking results clearly suggested a
binding mode for [Ala7]-1 (Figure 2A), which is characterized
by the indole moiety being in close contact with aromatic
residues (Y198, F200) and cis-Pro(OH)4 pointing towards the
actin R177/D179 salt bridge. 4Hyp4 interacts with S199 by
hydrogen-bonding, and T202 forms a hydrogen bond to the
backbone carbonyl group of Ala1. This model refines earlier
proposals[6a,c,23] and orients phalloidin roughly similar to the
binding mode anticipated by Lorenz et al.[6a] More specifi-
cally, all SAR data available on 1 are in agreement with the
binding geometry found here by unbiased docking.[6c,23,24,27,28]
[3] A. M. Lengsfeld, I. Low, T. Wieland, P. Dancker, W. Hasselbach,
[4] a) M. R. Bubb, I. Spector, B. B. Beyer, K. M. Fosen, J.Biol.
[5] a) B. Kunze, R. Jansen, F. Sasse, G. Höfle, H. Reichenbach, J.
Antibiot. 1995, 48, 1262 – 1266; b) F. Sasse, B. Kunze, T. M. A.
7
826 – 836; b) M. O. Steinmetz, D. Stoffler, S. A. Müller, W. Jahn,
B. Wolpensinger, K. N. Goldie, A. Engel, H. Faulstich, U. Aebi,
Interestingly, dye attachment to Leu(OH)2 of 1 does not
affect affinity.[7] This is in excellent agreement with our
binding model, where the Ala7-side chain extends into an
accessible cavity (Figure 1B) in the same region in which a
phalloidin-attached dye was located experimentally.[6c]
[7] Phalloidin fluorescently labeled at Leu7 is widely used to study
actin biology, see: E. Wulf, A. Deboben, F. A. Bautz, H.
The binding of chondramide C (3 = 14c) was investigated
in a similar fashion. Owing to the larger conformational
freedom of 14c, the size of the cavity, and limitations of the
available data (8 resolution),[6c] binding modes were
preferred that showed key interactions similar to the phalloi-
din pharmacophore.[29] In our best solution (Figure 1B) the
Trp side chain of 14c similarly interacts with aromatic amino
acid residues, and the Ala in 14c overlays with the respective
Ala5 of 1. The polyketide segment aligns well with the 4Hyp4
and Cys3 of 1, and the Tyr-OH group interacts with T202,
which has been predicted to contribute to binding of 1. In this
binding model of 14c the order of the residues is identical to 1,
despite the opposite Trp stereochemistry in phalloidin (l) and
chondramide C (d). Importantly, the model explains well the
influence of the stereogenic centers in the polyketide back-
bone of 3. Inversion of configuration at C7 attenuated activity
by 100-fold, presumably by populating unfavorable confor-
mations[30] in the peptide segment of chondramide C.
In summary, a total synthesis of chondramide C (3) was
accomplished featuring a rewarding E-selective ring-closing
metathesis as the key step. The excellent overall yield (34%
from 10) highlights the benefit of our swift solid-phase based
synthesis strategy, and chondramide C analogues were rapidly
assembled (19–38% from 10). Phenotypic actin assays
revealed C7 and the double bond in 3 as crucial stereogenic
elements for determining F-actin-stabilizing activity. Compu-
tational docking studies substantiated a pharmacophore
model for phalloidin (1) and provided a binding mode for
chondramide C (3 = 14c). These results are expected to guide
further developments of actin-stabilizing agents in the future.
Hirai, K. Yokota, T. A. Momose, Heterocycles 1994, 39, 603 –
[9] Independent from our research, Kalesse et al. have recently
succeeded in a total synthesis of chondramide C (U. Eggert, R.
Diestel, F. Sasse, R. Jansen, B. Kunze, M. Kalesse, Angew.Chem.
2008, 120, 6578 – 6582; Angew.Chem.Int.Ed. 2008, 47, 6478 –
6482.
[10] T.-S. Hu, R. Tannert, H.-D. Arndt, H. Waldmann, Chem.
[11] S. Rachid, D. Krug, K. J. Weissman, R. Müller, J.Biol.Chem.
183 – 186; b) S. G. Davies, N. M. Garrido, D. Kruchinin, O.
Ichihara, L. J. Kotchie, P. D. Price, A. J. P. Mortimer, A. J.
[14] a) Y. Ohfune, N. Kurokawa, N. Higuchi, M. Saito, M. Hashimoto,
[16] R. Tannert, M. Schürmann, H. Preut, H.-D. Arndt, H. Wald-
[17] a) M. D. Alexander, S. D. Fontaine, J. J. la Claire, A. G. di Pas-
K.-H. Altmann, Synlett 2007, 415 – 418; d) J. Jin, Y. L. Chen,
recent review see: e) A. Gradillas, J. Pꢁrez-Castells, Angew.
[19] A related case: D. Castoldi, L. Caggiano, L. Panigada, O. Sharon,
Received: March 2, 2008
Published online: July 15, 2008
Keywords: antitumor agents · drug design · metathesis ·
.
natural products · total synthesis
1285; b) A. Disanza, A. Steffen, M. Hertzog, E. Frittoli, K.
Rottner, G. Scita, Cell.Mol.Life Sci. 2005, 62, 955 – 970.
[20] Authentic 3 was kindly provided by the HZIBraunschweig
(Prof. Dr. M. Kalesse).
ꢀ 2008 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Angew. Chem. Int. Ed. 2008, 47, 6473 –6477